We all know that THC increases our appetite. But what about CBD? As it turns out , CBD has a surprising effect on metabolism. THC is associated with stimulating hunger causing munchies, this cannabinoid is capable of influencing metabolism. But does CBD affect. However, it turns out that the non-psychoactive part of the hemp plant (CBD) may affect our metabolism in a quite different way! If you're not.
and metabolism cbd
White fat cells can increase risk of heart disease, diabetes, among others. Brown fat alternatively can promote weight loss by burning energy. Researchers agreed that CBD has the ability to induce fat browning, or more simply put to turn white fat into brown fat. CBD interacts with the body with the help of the endocannabinoid system. In addition to signaling chemicals and receptors the endocannabinoid system is made up of metabolic enzymes, which is directly connected to several metabolic functions including storing energy and transporting nutrients, it may be involved with directing sensitivity to insulin.
The THC in cannabis affects metabolism which can increase appetite, but hunger is not the only thing it can stimulate. The endocannabinoid system stimulates other areas of the body involved in metabolism including the gastrointestinal tract, endocrine pancreas, and skeletal muscles, among others. The endocannabinoid system does the same things through 2 endogenous cannabinoids 2-Arachidonoylglycerol and anandamide which interface with CB1 and CB2 receptors which reside in various parts of the body including the digestive tract and brain.
CBD can assist metabolising compounds absorbed from food during digestion by prompting the two receptors. Over stimulating the endocannabinoid system can lead to abdominal obesity, insulin resistance and increased energy storage in fat cells. CB1 receptor when over stimulated can increase odds of developing metabolic syndrome which is associated with adverse symptoms such as high blood pressure, excess body fat, and high blood sugar among others.
It has been noted that CBD is a CB1 antagonist which may have the ability to treat such a condition and possibly others like it as well. Cannabinoids such as CBD can lower food intake and decrease weight gain. Recently, an 8-week trial studied the interaction of the anticonvulsant drug clobazam and CBD in 13 children with refractory epilepsy. Furthermore, CBD has been shown to interact in vitro with P-glycoprotein efflux transporters involved in multidrug resistance, and thus, it may affect the pharmacokinetics of anticancer drugs.
The identification of CBD metabolites has typically relied on mass spectral fragmentation patterns, and structural confirmation by synthesis was done only in a few cases; nevertheless, essentially all single-site modified CBD metabolites have been prepared. The aim of most of these syntheses was merely to verify the chemical structure of a metabolite and not to provide material for bioassays. The few exceptional studies were discussed in the preceding paragraphs.
Analytical characterizations of and synthetic methodologies for all five metabolites hydroxylated at the pentyl side chain were described in the early s. Chemical syntheses of metabolites oxidized at multiple sites have not been published. Several drugs used in therapy are metabolically converted into active metabolites and interindividual variations in the generation and pharmacokinetics of such active species may cause variability in the response to treatment by different individuals.
Pharmacological studies with such metabolites are scarce yet suggest interesting biological activities, which are unrelated or not directly related to CB receptors. Thus, intriguing questions arise:. Could any of the pharmacological effects observed for CBD be attributed to its metabolites? Are there any drug—drug interactions that affect the outcome of the therapeutic effects of other, non-CB medicines used concomitantly with CBD?
Could any of the metabolites be used as templates for the development of novel therapeutic agents? The pharmacological characterization of CBD metabolites both in vitro and in vivo is timely and necessary to shed light on the multifaceted, perplexing, or sometimes even contradictory biological properties observed for the parent CB.
The understanding of the clinical significance of these abundant metabolites in the proven therapeutic effects of CBD-containing preparations warrants further studies. Michael Evans-Brown is gratefully acknowledged for linguistic advice. Cite this article as: National Center for Biotechnology Information , U. Journal List Cannabis Cannabinoid Res v. Published online Mar 1. Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC.
Associated Data Supplementary Materials Supplemental data. Abstract Cannabidiol CBD , the main nonpsychoactive constituent of Cannabis sativa , has shown a wide range of therapeutically promising pharmacological effects either as a sole drug or in combination with other drugs in adjunctive therapy.
Open in a separate window. Human Pharmacokinetics of CBD Upon Various Administration Routes Extensive studies in animals, including rodents and the dog, indicate that a large portion of the administered CBD is excreted intact or as its glucuronide.
Chemical structures of CBD-derived substances of biological interest. Studies in animals There have been only a few in vivo investigations with selected monooxygenated metabolites. Human studies There are no publications describing the biological activity of CBD metabolites in humans. Interaction with other drugs The pharmacological actions of CBD on receptors, ion channels, cellular uptake processes, and enzymes have recently been reviewed 9—11 and are not reiterated here.
Synthesis of CBD Metabolites The identification of CBD metabolites has typically relied on mass spectral fragmentation patterns, and structural confirmation by synthesis was done only in a few cases; nevertheless, essentially all single-site modified CBD metabolites have been prepared. Summary Several drugs used in therapy are metabolically converted into active metabolites and interindividual variations in the generation and pharmacokinetics of such active species may cause variability in the response to treatment by different individuals.
Thus, intriguing questions arise: Supplementary Material Supplemental data: Click here to view. Acknowledgment Michael Evans-Brown is gratefully acknowledged for linguistic advice. Author Disclosure Statement No competing financial interest. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. Jacob A, Todd AR. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol.
Mechoulam R, Shvo Y. The structure of cannabidiol. ElSohly M, Gul W. Constituents of Cannabis sativa. Handbook of Cannabis Pertwee RG, editor. Gaoni Y, Mechoulam R.
Isolation, structure, and partial synthesis of an active constituent of hashish. Known pharmacological actions of nine nonpsychotropic phytocannabinoids. Molecular targets of cannabidiol in neurological disorders. Cannabidiol CBD and its analogs: Safety and side effects of cannabidiol, a Cannabis sativa constituent. Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Cannabidiol for neurodegenerative disorders: Br J Clin Pharmacol. Cannabidiol as potential anticancer drug.
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Gloss D, Vickrey B. Cochrane Database Syst Rev. The biology and potential therapeutic effects of cannabidiol. Food and Drug Administration. Warning letters and test results. Community register of orphan medicinal products: Metabolism and pharmacokinetics of the cannabinoids.
Biochemistry and physiology of substance abuse Watson RR, editor. Boca Raton, , pp. Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. Cannabinoid pharmacokinetics and disposition in alternative matrices. A review of the literature. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intraveous administration.
Biomed Environ Mass Spectrom. Metabolism of cannabinoids in man. New York, , pp. Assay of cannabinol and cannabidiol by mass fragmentography. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Controlled clinical trial of cannabidiol in Huntington's disease.
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.
A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts CBMEs GWPD plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a Cannabis Based Medicine Extract given via two administration routes GWPD Ext.
Eur J Clin Pharmacol. Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model. Cannabidiol bioavailability after nasal and transdermal application: Drug Dev Ind Pharm. Cannabinoids and appetite stimulation. The effect of orally and rectally administered deltatetrahydrocannabinol on spasticity: Int J Clin Pharmacol Ther.
Gronewold A, Skopp G. A preliminary investigation on the distribution of cannabinoids in man. Distribution of free and conjugated cannabinoids in human bile samples. Characterization of blood disappearance and tissue distribution of [ 3 H]cannabidiol. The effects of pharmaceutical excipients on drug disposition.
Adv Drug Deliv Rev. Pharmaceutical excipients influence the function of human uptake transporting proteins. The pharmacokinetic fate of cannabidiol and its relationship to barbiturate sleep time. Christiansen J, Rafaelsen OJ. Cannabis metabolites in urine after oral administration. Two cannabidiol metabolites formed by rat liver.
Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography—mass spectrometry. Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Identification of cytochrome P enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Shani A, Mechoulam R. Photochemical reactions of cannabidiol. Identification of cannabielsoin, a new metabolite of cannabidiol formed by guinea-pig hepatic microsomal enzymes, and its pharmacological activity in mice. Cannabielsoin as a new metabolite of cannabidiol in mammals.
HU, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J Pharmacol Exp Ther. HU and HU, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells.
Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis Due to extensive Phase I metabolism, the pharmacokinetics of CBD is. Cannabidiol (CBD) is a non-psychoactive ingredient of Cannabis sativa (Izzo et al., Splanchnic circulation and metabolism in patients with acute liver failure. The most prominent of those is cannabidiol (CBD). and inhibition of hepatic drug metabolism and drug transporters (e.g., p-glycoprotein).